Kindred Biosciences Inc
Change company Symbol lookup
Select an option...
KIN Kindred Biosciences Inc
EPTI Environmental Packaging Technologies Holdings Inc
SOIEF Stolt-Nielsen Ltd
ADP Automatic Data Processing Inc
VTMEF Vietnam Enterprise Investments Limited
REEAX RBC Emerging Markets Equity Fund Class A
RDPIX ProFunds Rising U.S. Dollar Fund Investor Class
MTPP Mountaintop Properties Inc
PVIVX Paradigm Micro-Cap Fund
PQARX Principal Spectrum Preferred and Capital Securities Income Fund Class R-4
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

Price
Delayed
$9.19
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 187 shares is on pace to be much lighter than KIN's 10-day average volume of 4,548,095 shares.

187

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.